About

Welcome to the Lupus Forum. The Lupus Forum is an educational website developed under the auspices of the University of Leeds and is dedicated to the dissemination of the latest developments in the field of lupus. It provides continuing medical education to clinicians around the globe to facilitate greater understanding of lupus, its treatments, and clinical practice.

Lupus Forum content is free from commercial bias, and feature leading experts sharing their knowledge and experience in the form of video tutorials.

Membership of the Lupus Forum is free to everyone. Register as a member and have unlimited free access to all of the materials contained within the site.

View our ACR 2025 Resources
Register here!
Register here!
View our latest Therapy Essentials

NEW Monthly literature search podcasts – available now

Join Professor Chris Edwards and Dr Alice Mason as they discuss EULAR recommendations for a core dataset in SLE and the efficacy and safety of upadacitinib as a monotherapy or combination with elsubrutinib for SLE. This podcast provides a valuable framework for guiding therapeutic decisions in SLE and also supporting clinical care and translational/observational research.

Latest Updates

Publications ▼
All
Publication thumbnail: EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosus

EULAR recommendations for a core dataset to support clinical care and translational and observational research in systemic lupus erythematosus

Publication thumbnail: CAR T cell therapy efficacy and safety in SLE: A systematic review and pooled analysis of 47 patients across 10 studies

CAR T cell therapy efficacy and safety in SLE: A systematic review and pooled analysis of 47 patients across 10 studies

Publication thumbnail: Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: A randomised, double-blind, placebo-controlled, Phase II study

Efficacy, pharmacokinetics and safety of iscalimab (CFZ533) in patients with proliferative lupus nephritis: A randomised, double-blind, placebo-controlled, Phase II study

Publication thumbnail: ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations

ERN ReCONNET–SLICC–SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations

Steering Committee